First-line pembrolizumab  + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

ConclusionFirst-line pembrolizumab plus chemotherapy demonstrated improvement in overall survival and progression-free survival compared with placebo plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer; safety was comparable between treatment groups.Clinical trial registryClinicalTrials.gov, NCT03189719.

Source: Esophagus - June 7, 2022 Category: Gastroenterology Source Type: research